Ig class switch recombination (CSR) is a long-range DNA recombination reaction that occurs between Ig switch regions (S regions) and that replaces the isotype expressed (from IgM to IgG, IgE, or IgA), providing novel effector functions for efficient antigen clearance ([@bib5]). CSR is initiated by the transcription-coupled recruitment of activation-induced cytidine deaminase (AID; [@bib3]; [@bib16]), an enzyme that deaminates cytosines into uracils in the single-strand DNA exposed by transcription ([@bib18]). During CSR, the choice of recombination to a particular isotype is determined by the activation of specific S region promoters ([@bib3]; [@bib16]), triggering the generation of noncoding germline transcripts ([@bib5]). Germline transcription precedes recombination, is induced at both the donor and acceptor S regions, and is required for recombination ([@bib5]). Transcriptional activation of the IgH locus during CSR is controlled by the Eμ enhancer located upstream of the donor (Sμ) S region and by a major regulatory region (RR) located at the 3′ end of the locus (3′ RR). Both of these enhancer elements are required for transcription and for CSR ([@bib5]; [@bib16]). The current model is that during CSR, recombination between S regions proceeds by the inducible formation of long-range DNA loops involving the S region promoters and the Eμ and 3′ RR enhancers ([@bib27]; [@bib13]), possibly through transcription factors ([@bib7]). Nevertheless, the molecular mechanisms controlling these conformational changes remain to be elucidated.

Mediator is an evolutionarily conserved multiprotein complex composed of 31 subunits organized in four modules that is required for gene transcription by RNA polymerase II (Pol II; [@bib14]; [@bib6]). The head, middle, and tail modules form a stable core complex that associates reversibly with the CDK8 module (consisting of cyclin-dependent kinase 8, cyclin C, Med12, and Med13) to control interactions of mediator with the Pol II machinery ([@bib14]; [@bib6]). Mediator behaves as an interface between Pol II and transcription factors and is capable of promoting Pol II preinitiation complex assembly, transcription initiation by Pol II, regulation of Pol II pausing and elongation, recruitment of transcription elongation factors, and control of the phosphorylation state of the C-terminal domain of Pol II ([@bib14]; [@bib6]; [@bib1]). The Med1 subunit of mediator, part of the middle module, interacts with distinct transcriptional activators ([@bib4]) and has been shown to play a key role in embryonic development ([@bib9]; [@bib31]), erythropoiesis ([@bib23]), and iNKT cell development ([@bib29]). In addition, Med1 recruitment to chromatin is one of the features that characterizes super enhancers ([@bib26]). Interestingly, mediator has also been implicated, together with cohesin, in the formation of long-range DNA loops ([@bib14]; [@bib6]; [@bib1]), and chromatin immunoprecipitation sequencing (ChIP-Seq) analysis for Smc1, Smc3, Med1, and Med12 revealed that cohesin--mediator binding predicts genomic sites of long-range promoter--enhancer interactions ([@bib12]; [@bib19]). As we have recently implicated the cohesin complex in the mechanism of CSR ([@bib24]), we have examined the role of mediator in CSR by performing shRNA-mediated knockdowns of the Med1 and Med12 subunits of mediator (belonging to different modules) in CH12 cells and by conditionally inactivating the Med1 subunit in developing B cells.

RESULTS AND DISCUSSION {#s01}
======================

The mediator complex is dynamically recruited to the IgH locus {#s02}
--------------------------------------------------------------

Mediator has been suggested to generate DNA loops by binding to promoters and enhancers in embryonic stem cells to induce gene expression ([@bib12]; [@bib19]). Recently, a ChIP-Seq experiment for the Med12 subunit of mediator performed on ex vivo--activated WT B cells has been reported ([@bib25]). Analysis of the available data (SRR975483) showed that in B cells induced to switch to IgG1 (LPS + IL-4), Med12 is significantly recruited at Eμ, the 3′ RR (hs1,2 and hs4), the γ1 promoter (γ1p), the Sγ1 S region, and a region downstream of Cγ1 containing a putative enhancer (γ1E; [@bib15]) that is also bound by Med1 in developing B cells ([@bib26]; [@bib20]).

To confirm these results and investigate the dynamics of mediator binding during CSR, we performed ChIP--quantitative PCR (qPCR) on resting B cells and B cells stimulated with LPS + IL-4 or LPS from control (*Med1^F/F^*) and *Med1*-deficient mice (*Med1^F/F^Mb1^Cre/+^*; see section CSR and transcription S regions are compromised by Med1 deficiency in primary B cells) using Med1- and Med12-specific antibodies. We used primer pairs spanning across the IgH locus: Eμ, the S region promoters (γ3p, γ1p, γ2bp), the γ1E enhancer, two elements of the 3′ RR bound by Med12 (hs1,2 and hs4), and Cγ2a as negative control. In control resting B cells, we found that Med1 and Med12 are exclusively recruited at the Eμ enhancer and at the hs1,2 and hs4 elements of the 3′ RR ([Fig. 1 A](#fig1){ref-type="fig"}). Binding was specific, as the ChIP signal was significantly enriched relative to *Med1*-deficient B cells. Upon CSR induction to IgG1 with LPS + IL-4, Med1 and Med12 are in addition recruited to γ1p and γ1E but not to γ3p and γ2p ([Fig. 1 B](#fig1){ref-type="fig"} and [Table S1](http://www.jem.org/cgi/content/full/jem.20141967/DC1){#supp1}). Conversely, stimulation with LPS, which induces CSR to IgG3 and IgG2b, leads to the specific recruitment of Med1 and Med12 to γ3p, γ2bp, and γ1E, but not to γ1p ([Fig. 1 C](#fig1){ref-type="fig"} and Table S1). Additionally, ChIP-qPCR for Med12 performed on *Med1*-deficient cells did not show reduced binding ([Fig. 1, A--C](#fig1){ref-type="fig"}; and Table S1), indicating that recruitment of Med12 is not dependent on Med1.

![**Med1 and Med12 are dynamically recruited to the IgH locus during CSR.** (A--C) Med1 and Med12 ChIP-qPCR experiments performed on chromatin prepared from 10^7^ splenic resting B cells (A) or cells stimulated with LPS + IL-4 (B) or LPS alone (C) for 72 h. qPCR was performed at the indicated locations (see [Table S3](http://www.jem.org/cgi/content/full/jem.20141967/DC1){#supp2} for primers). Results are expressed as the mean of the percentage input (+SD) from three independent biological replicate experiments. Statistical significance from WT results versus Cγ2a (two-tailed Student\'s *t* test) is indicated. \*, P ≤ 0.05; \*\*, P ≤ 0.01; \*\*\*, P ≤ 0.001. White bars represent ChIP performed on WT samples; black bars represent ChIP performed on *Med1*-deficient samples. See [Table S1](http://www.jem.org/cgi/content/full/jem.20141967/DC1){#supp3} for full statistical analysis. (D and E) Nuclear extracts (D) from CH12 cells and whole-cell extracts (E) prepared from WT splenic B cells stimulated with LPS + IL-4 for 72 h were immunoprecipitated and blotted with antibodies specific for Med1 and Med12. Input represents 1% of material used. Theoretical molecular masses in kilodaltons are indicated. Data are representative of two independent experiments.](JEM_20141967_Fig1){#fig1}

The Med1 and Med12 subunits, which belong to different modules of mediator, show similar recruitment profiles, suggesting that they are part of the same complex in B cells undergoing CSR. Consistent with this, we could show that Med1 and Med12 reciprocally coimmunoprecipitate from extracts prepared from both CH12 cells and ex vivo--activated splenic B cells ([Fig. 1](#fig1){ref-type="fig"}, [D](#fig1){ref-type="fig"} and [E](#fig1){ref-type="fig"}). We conclude that the mediator complex is dynamically recruited to the IgH locus at the promoters driving the transcription of acceptor S regions in a stimulation-specific manner and that Med12 can be recruited in the absence of Med1.

Knockdown of Med1 or Med12 impairs CSR and transcription of the acceptor S region in CH12 cells {#s03}
-----------------------------------------------------------------------------------------------

To investigate the functional significance of Med1 and Med12 recruitment to the IgH locus during CSR, we undertook knockdown experiments in CH12 cells, which can be efficiently stimulated to undergo CSR from IgM to IgA in vitro ([@bib24]). CH12 cells were transduced with lentiviruses expressing shRNAs specific for Med1 or Med12. As controls, we used a nontarget shRNA and AID-specific shRNA ([@bib24]). Knockdown efficiency was confirmed by Western blot ([Fig. 2 A](#fig2){ref-type="fig"}), and the ability of transduced cells to undergo CSR to IgA was determined by flow cytometry ([Fig. 2, B and C](#fig2){ref-type="fig"}). As expected, knockdown of AID resulted in a robust reduction in the efficiency of CSR (65%) relative to the nontarget shRNA control ([Fig. 2, B and C](#fig2){ref-type="fig"}). Similarly, knockdown of the Med1 or Med12 subunits resulted in a significant reduction in the efficiency of CSR (37%) relative to the nontarget shRNA (Med1 vs. nontarget: P = 3.66 × 10^−15^; Med12 vs. nontarget: P = 4.03 × 10^−10^; [Fig. 2, B and C](#fig2){ref-type="fig"}). The CSR defect observed was independent of abnormalities in AID expression as determined by Western blot ([Fig. 2 A](#fig2){ref-type="fig"}). We conclude that knockdown of Med1 and Med12 in CH12 cells results in defective CSR without affecting AID expression. To determine whether Med1 and Med12 knockdown affects S region transcription, we analyzed the level of donor (Iμ-Cμ) and acceptor (Iα-Cα) germline transcripts by real time (RT)--qPCR in CH12 cells expressing shRNAs specific for Med1, Med12, or a nontarget control ([Fig. 2, D and E](#fig2){ref-type="fig"}). Although the level of donor germline transcript was not affected ([Fig. 2 D](#fig2){ref-type="fig"}), we found that the level of the acceptor S region germline transcripts was significantly reduced upon Med1 and Med12 knockdown when compared with the nontarget control ([Fig. 2 E](#fig2){ref-type="fig"}). We conclude that Med1 and Med12 are required for robust transcription of the Sα acceptor S region.

![**Knockdown of Med1 or Med12 impairs CSR in CH12 cells.** (A) Knockdown efficiencies were determined by Western blot on transduced cells stimulated for 48 h and sorted for GFP expression. Western blots for β-actin, Med1, Med12, and AID are shown. Theoretical molecular masses in kilodaltons are indicated. Data are representative of three experiments. (B) IgA surface expression as determined by flow cytometry in stimulated CH12 cells transduced with a lentivirus expressing a GFP reporter and shRNAs specific for AID, Med1, Med12, and a nontarget shRNA negative control. Representative plots (gated on live cells) are shown. Percentage of cells in each quadrant is indicated, and the percentage of IgA^+^ cells among the GFP^+^ population is indicated in the upper right quadrants. (C) Percentage (+SD) of CSR relative to the nontarget shRNA control from four independent experiments by gating on cells expressing GFP. CSR in cells expressing the nontarget shRNA control was set to 100%. The difference in CSR efficiency between nontarget and shRNA knockdown (Δ) is indicated below. Statistical significance versus the nontarget shRNA control (two-tailed Student\'s *t* test) is indicated. (D and E) RT-qPCR for Iμ-Cμ (D) and Iα-Cα (E) germline transcripts in transduced cells stimulated for 48 h and sorted for GFP expression. Transcript cycle threshold values were normalized to hypoxanthine-guanine phosphoribosyltransferase mRNA abundance and are presented relative to the nontarget shRNA negative control (set as 1). Statistical significance versus the nontarget shRNA control (two-tailed Student\'s *t* test) is indicated. \*, P ≤ 0.05; \*\*, P ≤ 0.01; \*\*\*, P ≤ 0.0001. Data are representative of three independent experiments.](JEM_20141967_Fig2){#fig2}

CSR and transcription of acceptor S regions are compromised by *Med1* deficiency in primary B cells {#s04}
---------------------------------------------------------------------------------------------------

To inactivate the Med1 subunit in developing B cells, we bred *Med1*-floxed mice (*Med1^F/F^*; [@bib11]) with *Mb1^Cre/+^* knock-in mice ([@bib8]). Despite efficient Cre-mediated deletion (not depicted), normal B cell numbers (not depicted) and frequencies were found in the bone marrow and the spleen (not depicted). The only difference observed was an increase in the proportion of marginal zone relative to follicular B cells in the spleen of *Med1*-deficient mice (not depicted). Therefore, mature B cell populations in the spleen are efficiently generated in the absence of Med1.

To determine whether conditional inactivation of *Med1* results in defective CSR, we cultured in vitro CFSE-labeled splenic B cells isolated from *Med1^F/F^Mb1^Cre/+^* mice and control mice (*Med1^+/+^*, *Mb1^Cre/+^*, *Med1^F/F^*, or *Med1^F/+^Mb1^Cre/+^*) under conditions that induce CSR to different isotypes ([Fig. 3, A and B](#fig3){ref-type="fig"}). Although no differences were observed among the different control genotypes, interestingly, we found that *Med1* deficiency resulted in a 30--60% reduction in CSR to all isotypes tested ([Fig. 3, A and B](#fig3){ref-type="fig"}). To determine whether *Med1* deficiency affects AID expression, we measured the level of AID mRNA and protein in activated *Med1^F/F^Mb1^Cre/+^* and control B cells by RT-qPCR and Western blot ([Fig. 3 C](#fig3){ref-type="fig"}). We did not find any significant reduction in AID expression level in *Med1^F/F^Mb1^Cre/+^* mice compared with control mice ([Fig. 3 C](#fig3){ref-type="fig"}). Therefore, reduced CSR in *Med1*-deficient B cells cannot be explained by defective AID expression. In addition, the effect of *Med1* deficiency on CSR was not caused by decreased survival (not depicted), strong proliferation defects (not depicted), or defective cell cycle progression (not depicted), nor by an increased proportion of marginal zone B cells in *Med1^F/F^Mb1^Cre/+^* mice (not depicted). We conclude that *Med1* deletion results in a B cell--intrinsic CSR defect that is independent of defective AID expression or strong proliferation abnormalities.

![**CSR and acceptor S region transcription are compromised by *Med1* deficiency in primary B cells.** (A, left) Percentage (+SD) of CSR relative to control cells from three to six independent experiments. The genotypes tested and number of mice were as follows: *Med1^F/F^Mb1^Cre/+^* (*n* = 37), *Med1^+/+^* (*n* = 6), *Mb1^Cre/+^* (*n* = 4), *Med1^F/F^* (*n* = 28), *Med1^F/+^* (*n* = 11), or *Med1^F/+^Mb1^Cre/+^* (*n* = 16). No difference between control genotypes (*Med1^+/+^*, *Mb1^Cre/+^*, *Med1^F/F^*, *Med1^F/+^*, and *Med1^F/+^Mb1^Cre/+^*) was observed. CSR in control cells was set to 100%. Statistical analysis was performed using Student's *t* test. \*\*, P ≤ 0.01; \*\*\*, P ≤ 0.0001. Right: CSR to IgE was evaluated by the levels of Iμ-Cε post-switch transcripts by RT-qPCR in control and *Med1^F/F^Mb1^Cre/+^* B cells cultured for 72 h with LPS + IL-4. Expression is normalized to Igβ and is presented relative to expression in control B cells (set as 1). Mean and SD of triplicate samples are shown. Statistical analysis was performed using two-tailed Student's *t* test. \*\*, P ≤ 0.01. Data are representative of three experiments with two mice per genotype. (B) Representative example of surface expression of IgG1, IgG3, and CFSE dilution as determined by flow cytometry in *Med1^F/F^* and *Med1^F/F^Mb1^Cre/+^* B cells stimulated for 72 h with LPS + IL-4 or LPS alone. Percentage of switched cells is indicated. (C, top) RT-qPCR analysis for AID mRNA in control and *Med1^F/F^Mb1^Cre/+^* B cells cultured for 72 h with LPS + IL-4. Expression is normalized to Igβ and is presented relative to expression in control B cells (set as 1). Mean and SD of triplicate samples are shown. Statistical analysis was performed using two-tailed Student's *t* test. Data are representative of three experiments with two mice per genotype. Bottom: Western blot for β-actin and AID on whole-cell extracts from splenic B cells from *Med1^F/F^* and *Med1^F/F^Mb1^Cre/+^* mice cultured for 72 h with LPS and IL-4. Theoretical molecular masses in kilodaltons are indicated. Data are representative of three independent experiments. (D) RT-qPCR analysis for germline transcripts (GLT) at donor and acceptor S regions in *Med1^F/F^Mb1^Cre/+^* and control (*Med1^F/F^*) B cells cultured for 72 h with LPS alone or with LPS + IL-4 or LPS + IFN-γ. Expression is normalized to Igβ and is presented relative to expression in control B cells, set as 1. Mean and SD of triplicate samples are shown. Statistical analysis was performed using two-tailed Student's *t* test. \*, P ≤ 0.05; \*\*, P ≤ 0.01; \*\*\*, P ≤ 0.001. Data are representative of three independent experiments with two mice per genotype.](JEM_20141967_Fig3){#fig3}

To determine whether *Med1* deletion has a general impact on S region transcription, we measured the level of donor (Iμ-Cμ) and acceptor S region germline transcripts (Iγ1-Cγ1, Iγ3-Cγ3, Iγ2b-Cγ2b, and Iγ2a-Cγ2a) by RT-qPCR in activated *Med1^F/F^Mb1^Cre/+^* and control B cells ([Fig. 3 D](#fig3){ref-type="fig"}). We found that the level of Iμ-Cμ germline transcripts was increased by *Med1* deletion ([Fig. 3 D](#fig3){ref-type="fig"}), consistent with the fact that these transcripts accumulate when CSR is not efficient ([@bib24]). Interestingly, however, we found that the level of all the acceptor S region germline transcripts was significantly reduced in *Med1*-deficient B cells when compared with control B cells ([Fig. 3 D](#fig3){ref-type="fig"}). This is consistent with reduced levels of Sα transcripts resulting from Med1 or Med12 knockdown in CH12 cells ([Fig. 2 E](#fig2){ref-type="fig"}). We conclude that Med1 is required for robust transcription of the acceptor S regions. This could be explained by two nonmutually exclusive hypotheses. Med1 could be required to initiate transcription at the acceptor S region promoters. Alternatively, Med1 could mediate the long-range interactions between the IgH enhancers and the acceptor S region that are necessary to activate transcription, to bring the acceptor S region to the proximity of Sμ and to successfully undergo CSR.

*Med1* deficiency results in reduced interactions between Eμ and the Cγ3, Cγ1, Cγ2b, and Cε genes {#s05}
-------------------------------------------------------------------------------------------------

To evaluate whether the dynamic three-dimensional changes occurring at the IgH locus during CSR are dependent on the Med1 subunit of the mediator complex, we performed high-resolution 4C-Seq (circular chromosome conformation capture) experiments on resting and activated B cells isolated from the spleens of *Med1^F/F^Mb1^Cre/+^* and control (*Med1^F/F^*) mice ([Fig. 4](#fig4){ref-type="fig"} and not depicted). Purified B cells from three different mice per genotype were cultured (or not) for 48 h in the presence of LPS and IL-4 to induce CSR to IgG1 or with LPS alone to induce CSR to IgG3 and IgG2b. As a viewpoint, we used a bait located at the Eμ enhancer.

![***Med1* deficiency affects IgH chromatin dynamics during CSR.** (A and B) High-resolution 4C-Seq was performed using a bait on the Eμ enhancer (red dot). A schematic map of the IgH locus indicates the I exons (black dots), S regions (gray boxes), the constant region exons (white boxes), the Eμ enhancer, the γ1 enhancer (γ1E), and the DNaseI hypersensitive sites (hs) located in the 3′ RR. Curved lines indicate long-range interactions. 4C-Seq signal was calculated using 10-kb windows centered on DpnII sites located in the constant region of IgH (chr12: 113175000--113475000, mm10). Full lines represent the mean of three replicates and dashed lines the signal for each replicate. The 4C-Seq analysis was conducted with three biological replicates per time point (day 0 and day 2), genotype (*Med1^F/F^* and *Med1^F/F^Mb1^Cre/+^*), and stimulation: resting B cells and LPS + IL-4--stimulated cells (A) and resting B cells and LPS-stimulated cells (B). We focused our analysis on the RRs and on the regions whose transcription is specifically induced upon stimulation with LPS or LPS + IL-4 (black bars). In this focused analysis, a Welch's *t* test (two-sample and two-sided) was used on the mean score for all windows centered within the chosen regions to assess significant differences, taking into account the three replicates for each sample. P-values are indicated. The γ2bp-Sγ2b region is indicated with an arrow.](JEM_20141967_Fig4){#fig4}

In control resting B cells, we observed a strong interaction between the two IgH enhancers, Eμ and 3′ RR, that was substantially increased upon activation ([Fig. 4](#fig4){ref-type="fig"} and not depicted). This is consistent with the long-range interactions described in primary B cells and in CH12 B cells ([@bib27]; [@bib17]) and with the promoter--enhancer interactome of the IgH locus revealed by Pol II ChIA-PET in primary B cells ([@bib21]). We also observed close-range contacts between Eμ and the Cμ and Cδ genes in resting B cells, which were diminished upon stimulation ([Fig. 4](#fig4){ref-type="fig"} and not depicted). Consistent with the fact that culturing B cells with LPS and IL-4 induces CSR primarily to IgG1, we observed a significant increase in the interaction between Eμ and the γ1 promoter (γ1p), Sγ1, and the γ1E enhancer ([Fig. 4](#fig4){ref-type="fig"} and not depicted). Conversely, LPS stimulation led to a significant increase in the interaction between Eμ and the γ2b promoter and Sγ2b, as well as the γ1E enhancer. Importantly, no interaction was detected between Eμ and Sγ1 ([Fig. 4](#fig4){ref-type="fig"} and not depicted), confirming that the formation of loops involving recombining acceptor S regions is stimulation dependent ([@bib27]). The γ3 promoter and the Sγ3 S region appear to be involved in a constitutive interaction with Eμ in resting B cells ([Fig. 4](#fig4){ref-type="fig"} and not depicted). Although this interaction is significantly lost when B cells are stimulated to undergo CSR to IgG1 or IgE but not IgG3 (LPS + IL-4; [Fig. 4](#fig4){ref-type="fig"} and not depicted), it is maintained when B cells are stimulated to undergo CSR to IgG3 but not IgG1 or IgE (LPS alone; [Fig. 4](#fig4){ref-type="fig"} and not depicted).

Interestingly, the three-dimensional contacts revealed by 4C-Seq in control activated B cells ([Fig. 4](#fig4){ref-type="fig"} and not depicted) perfectly correlate with Med1 and Med12 binding ([Fig. 1](#fig1){ref-type="fig"}). In *Med1^F/F^Mb1^Cre/+^* B cells, architectural changes within the IgH locus exhibit a similar profile upon activation ([Fig. 4](#fig4){ref-type="fig"} and not depicted). Nevertheless, the long-range interactions between Eμ and the γ1p-Sγ1 region and γ1E enhancer were no longer significant ([Fig. 4](#fig4){ref-type="fig"} and not depicted). This suggests a role for Med1 in facilitating these chromosomal interactions that occur after activation.

Across the entire IgH locus, no significant differences could be detected when comparing activated *Med1^F/F^Mb1^Cre/+^* with control B cells ([Fig. 4](#fig4){ref-type="fig"}). However, when we focused our analysis on the regions whose interactions with Eμ change upon activation and whose transcription is induced in a stimulation-dependent manner ([Fig. 4](#fig4){ref-type="fig"}), we detected significant differences between *Med1^F/F^Mb1^Cre/+^* and control B cells ([Fig. 4](#fig4){ref-type="fig"}). Notably, the interaction between Eμ and the γ1p-Sγ1 region and γ1E enhancer was significantly reduced (P = 0.01 and P = 0.05, respectively) in activated (LPS + IL-4) *Med1^F/F^Mb1^Cre/+^* B versus control B cells ([Fig. 4 A](#fig4){ref-type="fig"}). This shows that the Cγ1 gene is not efficiently brought into close proximity with Sμ in *Med1*-deficient B cells. Similarly, Eμ-γ2bp-Sγ2b interactions induced by LPS tend to be less frequent in *Med1*-deficient B cells ([Fig. 4 B](#fig4){ref-type="fig"}). The lower robustness of CSR induction by LPS alone (when compared with LPS + IL-4), in which only a small percentage of cells underwent CSR ([Fig. 3 B](#fig3){ref-type="fig"}), could explain why these interactions are not as frequent in control cells and why the difference between *Med1*-deficient and control B cells is not more pronounced.

Altogether, the decrease in interactions observed in *Med1*-deficient B cells relative to control B cells ([Fig. 4](#fig4){ref-type="fig"}) is consistent with the reduction in acceptor S region transcription ([Fig. 3 D](#fig3){ref-type="fig"}) and the defect in CSR observed ([Fig. 3, A and B](#fig3){ref-type="fig"}). We conclude that the long-range contacts occurring in resting B cells between both of the IgH enhancers are robust and remain intact upon *Med1* deletion. In contrast, the dynamic three-dimensional changes occurring at the IgH locus upon activation between Eμ and the Cγ3, Cγ1, Cγ2b, and Cε genes are facilitated by the Med1 subunit of the mediator complex. It is impossible, however, to determine whether the reduced frequency of interaction between Eμ and the C genes observed in *Med1*-deficient B cells is the cause or the consequence of reduced transcription at the acceptor S regions.

*Med1* deficiency results in a 50% reduction in the efficiency of CSR, and it is possible that those B cells, which successfully underwent CSR in the absence of Med1, managed to properly synapse and transcribe the donor and acceptor S regions by a mediator-independent mechanism. Alternatively, as the Med12 subunit can be recruited to the IgH locus in the absence of Med1 ([Fig. 1, A and B](#fig1){ref-type="fig"}) and mediator complexes lacking the Med1 subunit can exist ([@bib4]; [@bib1]), it is possible that the *Med1*-deficient B cells that managed to undergo CSR were able to assemble and recruit a mediator complex independently of the Med1 subunit. Our results implicate the mediator complex in the mechanism of CSR and are consistent with a model in which mediator, possibly together with cohesin, facilitates the transcriptional activation of S regions and their long-range contacts with the IgH locus enhancers during CSR.

MATERIALS AND METHODS {#s06}
=====================

 {#s07}

### Mice {#s08}

*Mb1^Cre/+^* mice ([@bib8]) were obtained from M. Reth (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany). *Med1^F/F^* ([@bib11]) and *Mb1^Cre/+^* mice were on a B6/129 mixed background and bred and maintained under specific pathogen--free conditions. 8--12-wk-old mice were used in all experiments. All animal work was performed under protocols approved by the Direction des Services Vétérinaires du Bas-Rhin (authorization number 67-343).

### Lentiviral transduction {#s09}

The lentiviral vectors (pLKO.1 and pLKO.1-puro-CMV-TurboGFP) expressing shRNAs specific for AID (TRCN0000112031), Med1 (TRCN0000099576), Med12 (TRCN0000096466), or a nontarget control (SHC002) were obtained from Sigma-Aldrich. CH12 cells were infected with viral particles produced in Lenti-X 293T cells as described previously ([@bib24]).

### Cell culture and flow cytometry {#s10}

Resting splenic B cells were isolated using CD43 microbeads (Miltenyi Biotec), stained with 5 µM CFSE (Invitrogen), and cultured for 72 h with 50 µg/ml LPS (Sigma-Aldrich) to switch to IgG3 and IgG2b, LPS and IL-4 (5 ng/ml; PeproTech) to switch to IgG1, and LPS and IFN-γ (100 ng/ml; PeproTech) to switch to IgG2a. CSR was assayed by flow cytometry as described previously ([@bib10]). CH12 cells were transduced with shRNA-expressing lentiviral vectors and were cultured with IL-4, TGF-β, and anti-CD40 antibody to switch to IgA as described previously ([@bib24]). After 72 h, enhanced GFP expression and surface IgA was analyzed by flow cytometry.

### Western blot analysis {#s11}

Proteins were fractionated by SDS-PAGE on 4--12% gradient gels (Invitrogen), transferred to Immobilon polyvinylidene difluoride membranes (EMD Millipore), and analyzed by Western blot. See [Table S2](http://www.jem.org/cgi/content/full/jem.20141967/DC1){#supp4} for antibodies used in this study.

### ChIP-qPCR {#s12}

Analytical scale ChIP was performed on chromatin prepared from 10^7^ (resting or activated) splenic B cells isolated from a pool of two to three mice as described previously ([@bib28]). qPCR was performed at several locations across the IgH locus using primers listed in [Table S3](http://www.jem.org/cgi/content/full/jem.20141967/DC1){#supp5}. Results are expressed as percent input and represent the mean of three biological replicates. Error bars represent the corresponding SD.

### ChIP-Seq analysis {#s13}

Sequence reads (SRR975483 \[[@bib25]\] and SRR620145 \[[@bib26]; [@bib20]\]) were mapped to reference genome mm10/GRCm38 using Bowtie v1.12.8. Peak calling was performed using MACS ([@bib30]) with default parameters.

### RT-qPCR {#s14}

RNA and cDNA were prepared using standard techniques. qPCR was performed in triplicates using the Universal Probe Library system (Roche) or SyberGreen (QIAGEN) and a LightCycler 480 (Roche). Transcript quantities were calculated relative to standard curves and normalized to β-actin, Igβ, or hypoxanthine-guanine phosphoribosyltransferase (HPRT) mRNA. See Table S3 for primers and probes used in this study.

### High-resolution 4C-Seq {#s15}

4C-Seq was performed as described previously ([@bib22]). The primary restriction enzyme used was DpnII and secondary restriction enzyme Csp6I. Primers for the Eμ bait were 5′-TCTGTCCTAAAGGCTCTGAGA-3′ and 5′-GAACACAGAAGTATGTGTATGGA-3′. The 18 samples (three biological replicates, two genotypes, and three stimulation conditions) were sequenced on a HiSeq2500 rapid run using 50 cycles. Mapping was done using Bowtie, allowing for zero mismatches against a reduced genome containing all unique 24 bp surrounding every DpnII site in the genome. Between 2 and 4 million mapped reads were obtained for all samples, and at least half of the reads were mapped to chromosome 12. DESeq 1.6.0 was used to normalize raw read count in 10-kb windows centered on each DpnII site in the constant region of IgH (chr12: 113175000--113475000, mm10; [@bib2]). The following parameters were used with the estimateDispersion function: method = pooled, sharingMode = maximum. The nbinonTest function was used to determine which windows have a significantly different 4C-Seq signal. An adjusted p-value of 0.01 after Benjamini-Hochberg false discovery rate correction was used as a cutoff. For the analysis of specific regions, a Welch's *t* test (two-sample and two-sided) on the mean score for all windows centered within the chosen regions was used to assess significant differences, taking into account the three replicates for each sample. The coordinates used were as follows: Eμ-Sμ, chr12:113423031--113428514; Cμ-Cδ, chr12:113384000--113420500; γ3p-Sγ3, chr12:113361533--113371500; γ1p-Sγ1, chr12:113332600--113349000; γ1E, chr12:113319346--113325934; γ2bp-Sγ2b, chr12:113310111--113315500; εp-Sε, chr12:113273549--113280029; hs1,2-hs3A, chr12:113242500--113255414; and hs3B/hs7, chr12:113220000--113233375.

### Accession number {#s16}

4C-Seq data on resting and activated, control, and *Med1*-deficient B cells were submitted to the Gene Expression Omnibus (accession number [GSE62969](GSE62969){#dblnk3dfc21a2-545c-5220-44b0-6411fdfa46ed}).

### Online supplemental material {#s17}

Table S1 includes statistics for ChIP-qPCR ([Fig. 1](#fig1){ref-type="fig"}). Table S2 lists antibodies used in this study. Table S3 lists primers and probes used in this study. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20141967/DC1>.
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